Exchange: HKSE Sector: Healthcare Industry: Medical Distribution
-4.15% HKD13.40
America/New_York / 3 mai 2024 @ 03:56
FUNDAMENTALS | |
---|---|
MarketCap: | 1 447.20 mill |
EPS: | 0.510 |
P/E: | 26.27 |
Earnings Date: | Mar 29, 2024 |
SharesOutstanding: | 108.00 mill |
Avg Daily Volume: | 0.146 mill |
RATING 2024-04-30 |
---|
A- |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Buy | |
Return On Asset: | Buy | |
DE: | Strong Buy | |
P/E: | Neutral | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/21 | 4/21 | 2/22 | 4/22 | 2/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.76x |
Company: PE 26.27 | sector: PE 34.76 |
PE RATIO: COMPANY / INDUSTRY |
---|
1.99x |
Company: PE 26.27 | industry: PE 13.23 |
DISCOUNTED CASH FLOW VALUE |
---|
HKD-8.12 (-160.61%) HKD-21.52 |
Date: 2024-05-03 |
Expected Trading Range (DAY) |
---|
HKD 12.93 - 14.03 ( +/- 4.10%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | HKD13.40 (-4.15% ) |
Volume | 0.0040 mill |
Avg. Vol. | 0.146 mill |
% of Avg. Vol | 2.74 % |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Charmacy Pharmaceutical Co., Ltd. engages in the trading of pharmaceutical products in the People's Republic of China. The company offers western medicines, Chinese patent medicines, healthcare products, and related consulting services to downstream distributors and terminal chemists. It also operates Charmacy e-Medicine, a B2B e-commerce platform to place orders online and make inquiries and payments. The company was formerly known as Chuangmei Pharmaceutical Co., Ltd. and changed its name to Charmacy Pharmaceutical Co., Ltd. in July 2016. Charmacy Pharmaceutical Co., Ltd. was incorporated in 1984 and is headquartered in Shantou, the People's Republic of China.